- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOMED LUBLIN Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 60,06 | +0,20 % | Novonesis (Novozymes A/S): Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe | Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe
A new report reveals that biosolutions could generate EUR 133 billion in economic gains and... ► Artikel lesen | |
| GENMAB | 186,30 | +1,83 % | Genmab reports Q2 Darzalex net sales of $3.54 billion | ||
| ARBUTUS BIOPHARMA | 2,752 | +2,15 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update | Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,510 | -100,00 % | Moleculin Biotech, Inc.: Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans | Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial Recent EU approval from the European Medicines Agency (EMA) boosts... ► Artikel lesen | |
| VERICEL | 31,600 | 0,00 % | Vericel Corporation: Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance | Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 MillionApproximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 2,813 | -100,00 % | Sensei Biotherapeutics, Inc. - 8-K, Current Report | ||
| MUSTGROW BIOLOGICS | 0,526 | +3,14 % | MustGrow Biologics Corp. Announces Results of Shareholder Meeting | Saskatoon, Saskatchewan--(Newsfile Corp. - June 26, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the results of its... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,360 | -100,00 % | BioXcel Therapeutics, Inc. - 8-K, Current Report | ||
| REGENXBIO | 7,300 | +2,82 % | REGENXBIO Inc.: REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy | Construct including CT domain demonstrated higher levels of microdystrophin protein, increased muscle force, and improved resistance to damage in mice lacking... ► Artikel lesen | |
| AKEBIA | 3,368 | +0,78 % | Akebia auf H.C. Wainwright Konferenz: Strategische Einblicke in Nierenmedikamente | ||
| FENNEC PHARMACEUTICALS | 7,700 | +4,05 % | Fennec Pharmaceuticals Inc.: Fennec Announces Results of Annual Meeting | RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the "Company") (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 11,100 | +0,91 % | Cantor Fitzgerald raises Zevra Therapeutics stock price target to $29 on NPC drug progress | ||
| REVANCE THERAPEUTICS | 3,420 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 07.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 07.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 07.02.2025ISIN NameCA09226M1005 BLACK... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 3,540 | -1,67 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis | SOUTH SAN FRANCISCO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application submitted... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 11,200 | +6,67 % | Wedbush initiates coverage on Cartesian Therapeutics stock with Outperform rating |
Das Unternehmen BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,004 (-0,33 %) liegt der Kurs bei 1,198 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA finden Sie auf Wallstreet Online.